Summit Therapeutics PLC Sponsored ADR Aktie News

I'm rating Summit Therapeutics a 'cautious Buy' based on the promising dual-action lung cancer therapy Ivonescimab and significant insider buying. SMMT's Ivonescimab targets non-small cell lung cancer through its dual Anti-PD-1 plus Anti-VEGF mechanism, with the potential to outperform the benchmarks. While there's a lot of uncertainty regarding sales and even more to earnings, valuation sugges...

Summit Therapeutics Inc. ( SMMT ) Jefferies London Healthcare Conference 2025 November 18, 2025 10:30 AM EST Company Participants Dave Gancarz - Chief Business & Strategy Officer Manmeet Soni - COO, CFO & Director Conference Call Participants Yuxi Dong - Jefferies LLC, Research Division Clara Dong Presentation Yuxi Dong Jefferies LLC, Research Division All right. Good afternoon.

Summit Therapeutics Inc. ( SMMT ) UBS Global Healthcare Conference 2025 November 10, 2025 3:30 PM EST Company Participants Dave Gancarz - Chief Business & Strategy Officer Manmeet Soni - COO, CFO & Director Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division All right, everyone. Thank you for joini...

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that our partner, Akeso, Inc. (“Akeso,” HKEX Code: 9926.HK) published results from the Phase III HARMONi-A trial, conducted in China and sponsored by Akeso, featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab. The data was presented ...

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at four upcoming investor conferences during the remainder of this year. Members of the Summit leadership team will participate in fireside chats and individual investor meetings at the following conferences: UBS Global Healthcare C...

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that results from the Phase III HARMONi-A trial, conducted in China and sponsored by our partner, Akeso, Inc. (“Akeso,” HKEX Code: 9926.HK), featuring the novel, potential first-in-class investigational bispecific antibody, ivonescimab, will be presented as part of the An...

A company's comeback story can mean a significant opportunity for investors to win returns in the financial world. Of course, when a stock has shed a sizable portion of its value in recent memory, many investors prefer to exercise caution unless there is a clear signal that the firm's fortunes could turn around.

Insider buys can be a telltale sign of a turnaround, as these investments give you a window into where management stands with a company.